Solid Phase I Results For AstraZeneca COVID-19 Vaccine, But Two Doses Needed To Hit Efficacy Goal
Investigators Highlight Promising T-Cell Response
Oxford is racing ahead in its Phase III trials, having dosed nearly all its target of 10,000 volunteers. 
